- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05785026
Menthol for Dyspnea Relief in Health and COPD (MENTHODYSC)
March 14, 2023 updated by: Daniel Langer, KU Leuven
Effectiveness and Mechanisms of Menthol Inhalation for the Relief of Dyspnea in Health and COPD
Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown.
The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The project is structured in 4 work packages (WP), each including a different sample of healthy volunteers (WP1, 2) or patients with COPD (WP3, 4), respectively with a 1:1 female/male ratio in each WP.
Each WP will be single-blind, placebo-controlled cross-over trial to investigate the effects of MI compared to placebo in healthy volunteers during resistive loaded breathing (WP1), in healthy volunteers during cycling exercise (WP2), in people with COPD who have dyspnea at rest (WP3), and in people with COPD during cycling exercise (WP4).
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Daniel Langer
- Phone Number: +32 16 37 64 97
- Email: daniel.langer@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- University Hospital Leuven
-
Principal Investigator:
- Daniel Langer
-
Sub-Investigator:
- Andreas von Leuopoldt
-
Principal Investigator:
- Wim Janssens
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18 years of age or older
- Able to speak, read, and write Dutch or English
- Normal pulmonary function: forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio>0.70; FEV1≥80%predicted (WP1 and 2 only)
- Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2 only)
- Clinically stable COPD (based on clinical judgment of the study physician that have not had exacerbations requiring escalation of medical therapy (i.e., short course of oral corticosteroids or antibiotics) within the preceding 14 days (WP3 and 4 only)
Exclusion Criteria:
- Contraindication to exercise testing (e.g., significant cardiovascular, musculoskeletal, neurological disease; see Table 4 from ERS/ATS consensus statement)
- Significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could influence dyspnea and/or impair exercise capacity (with the exception of COPD in WP3 and 4)
- Body mass index <18.5 or >35 kg/m2
- An ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery
- Severe facial trauma including cribriform plate disruption (bone separating brain from nasal cavity)
- Allergies to latex and sensitivities to local anesthetics
- Inability to give informed consent, including those with significant cognitive impairment
- Alcohol consumption within 12 hours of study visit
- Current smoker*
- History of early menopause (age <45 years)
- Pregnancy or desire to become pregnant while in trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WP 1a
Menthol inhalation during resistive loaded breathing trials in healthy participants.
|
300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Placebo Comparator: WP 1b
Strawberry scent during resistive loaded breathing trials in healthy participants.
|
600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Experimental: WP 2a
Menthol inhalation during cycle exercise in healthy participants.
|
300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Placebo Comparator: WP 2b
Strawberry scent during cycle exercise in healthy participants.
|
600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Experimental: WP 3a
Menthol inhalation during resting breathing in dyspneic COPD participants.
|
300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Placebo Comparator: WP 3b
Strawberry scent during resting breathing in dyspneic COPD participants.
|
600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
No Intervention: WP 3c
Resting breathing in dyspneic COPD participants.
|
|
Experimental: WP 4a
Menthol inhalation during cycle exercise in COPD participants.
|
300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
Placebo Comparator: WP 4b
Strawberry scent during cycle exercise in COPD participants.
|
600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in respiratory-related evoked potentials (RREP) with menthol vs. strawberry.
Time Frame: 1 week
|
RREPs will be measured using an electroencephalogram (EEG) sensor cap connected to a high-density 129 channel EEG system during breathing trials and exercise tests.
Inspiration will briefly be interrupted for 150 milliseconds every two to six breaths by activation of the occluder, which induces the RREP in the EEG signal.
|
1 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in diaphragmatic electromyography with menthol vs. strawberry.
Time Frame: 1 week
|
Diaphragmatic electromyography will be measured using a multi-pair electrode catheter during breathing trials and exercise tests.
and used as an index of neural respiratory drive.
|
1 week
|
Difference in dyspnea with menthol vs. strawberry.
Time Frame: 1 week
|
Dyspnea ratings will be measured using the Borg 0-10 category ratio scale and will be assessed at the end of each 5-minute breathing trial (WP1 and 3) and at baseline, every minutes during, and at peak of each cycle exercise test (WP2 and 4).
0 represents no dyspnea at all and then 10 the most maximal dyspnea ever experienced or could be imagined experiencing.
|
1 week
|
Difference in the rate of perceived inspiratory airflow
Time Frame: 1 week
|
Participants will be asked: "In which of the two conditions did your airflow feel easier when breathing in?" at the end of each study visit.
|
1 week
|
Perception of a cooling sensation
Time Frame: 1 week
|
Participants will be asked: "In which of the two conditions did you feel a fresh or cooling sensation when breathing in?" at the end of each study visit.
|
1 week
|
Difference in activation of extra-diaphragmatic inspiratory muscles with menthol vs. strawberry.
Time Frame: 1 week
|
Activation of extra-diaphragmatic inspiratory muscles will be measured using bipolar surface electrodes during breathing trials and exercise testing.
|
1 week
|
Difference in the cardiorespiratory responses to exercise with menthol vs. strawberry.
Time Frame: 1 week
|
Cardiorespiratory responses to exercise will be measured on a breath-by-breath basis using a commercially available cardiopulmonary testing system during exercise testing.
|
1 week
|
Difference in respiratory pressures with menthol vs. strawberry
Time Frame: 1 week
|
Respiratory pressures will be measured using esophageal and gastric balloons during breathing trials and exercise testing.
|
1 week
|
Difference in leg discomfort ratings with menthol vs. strawberry.
Time Frame: 1 week
|
Leg discomfort will be measured using the Borg 0-10 category ratio scale at baseline, every minute during, and at peak of each cycle exercise test (WP2 and 4).
0 represents no leg discomfort at all and then 10 the most maximal leg discomfort ever experienced or could be imagined experiencing.
|
1 week
|
Difference in exercise endurance time with menthol vs. strawberry.
Time Frame: 1 week
|
Exercise endurance time will be measured during submaximal constant load cycle exercise testing (WP 2 and 4).
|
1 week
|
Difference in the reasons for stopping exercise with menthol vs. strawberry.
Time Frame: 1 week
|
Participants will be asked to give their reasons for stopping (e.g., "breathing discomfort," "leg discomfort," "a combination of breathing and leg discomfort," or "other") and attributing a percentage to each of breathing discomfort and leg discomfort to total 100 (WP 2 and 4).
|
1 week
|
Difference in ratings of affective state on the dimensions of valence and arousal with menthol vs. strawberry.
Time Frame: 1 week
|
Dimensions of valence and arousal will be measured using the 9-point SAM scale at the end of each breathing trial (WP 1 and 3) and at peak exercise (WP 2 and 4).
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daniel Langer, KU Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Anticipated)
December 31, 2026
Study Completion (Anticipated)
June 30, 2027
Study Registration Dates
First Submitted
February 7, 2023
First Submitted That Met QC Criteria
March 14, 2023
First Posted (Actual)
March 27, 2023
Study Record Updates
Last Update Posted (Actual)
March 27, 2023
Last Update Submitted That Met QC Criteria
March 14, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S66762
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Menthol inhalation
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA); Brown University; National Institutes... and other collaboratorsCompletedSmoking (Tobacco) AddictionUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); University of MinnesotaRecruitingSmoking Prevention and ControlUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI); National Institutes of Health (NIH); National...CompletedCigarette Smoking ToxicityUnited States
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)CompletedTobacco Use DisorderUnited States
-
Yale UniversityRecruiting
-
Altria Client Services LLCCelerionRecruiting
-
University of Sao PauloUniversidade Estadual de LondrinaCompleted
-
Hospital de MataróCompleted
-
Philip Morris Products S.A.Completed
-
University of Sao PauloUniversidade Estadual de LondrinaUnknownThirst | Perioperative NursingBrazil